News

November 1, 2017
Integrated Biotherapeutics Inc. Partners with CARB-X the first Toxoid based Multivalent Vaccine for MRSA

CARB-X awards Integrated Biotherapeutics Inc. to develop a new breakthrough vaccine for the prevention of serious drug-resistant infections known as MRSA.  The award commits funding in an initial period with the possibility of an increase based on the achievement of milestones to the satisfaction of CARB-X.  

Read More

ExpreS2ion enters multi-product agreement with US-based Integrated BioTherapeutics for expansion of their commercial reagents portfolio

Hørsholm, Denmark, July 17, 2017-ExpreS2ion Biotech Holding AB announces that the fully owned subsidiary ExpreS2ion Biotechnologies ApS (“ExpreS2ion”) has entered a Master Services Agreement and a Research & Commercial License Agreement with the US based Integrated BioTherapeutics, Inc. (“IBT”). The agreements enable standardised activation of a range of services and products from ExpreS2ion. This primarily targets the development and manufacturing of proteins based on the ExpreS2 platform, as well as granting IBT commercial rights to promote, sell and distribute such protein products made with ExpreS2.

Read More

Immunization-elicited Antibody Shows Universal Protection against Multiple Ebolaviruses

ROCKVILLE, Md., May 18, 2017 /PRNewswire/ -- In research published online today in Cell, a team of scientists describe an antibody called CA45, elicited by immunization of nonhuman primates (NHP) that binds to a region of the Ebola virus surface protein that is shared among all pathogenic ebolaviruses.

Read More

IBT Receives Phase II STTR from NIAID for development of Bispecific Antibodies against multiple Ebolaviruses

IBT and Albert Einstein College of Medicine (EINSTEIN) receive a collaborative STTR grant from NIH, entitled Broadly Protective Bispecific Antibodies for Treatment of Ebola Virus Disease. A major challenge in the fight against filovirus infections is the fact that the nature of epidemics cannot be predicted. Beside the Zaire strain of Ebolavirus other ebolaviruses such as Sudan virus, Bundibugyo virus as well as the more distant relative Marburg virus have caused highly lethal outbreaks. As the nature of future ebolavirus disease outbreaks cannot be predicted, development of broadly protective immunotherapeutics for ebolaviruses is urgently needed.

Read More

IBT Receives a Partnership R01 grant from NIAID to Develop a Pan-Ebolavirus Vaccine

IBT and The Scripps Research Institute (TSRI) receive a collaborative Partnership R01 grant from NIH, entitled Rationally Designed Pan-Ebolavirus Vaccine. A major challenge in the fight against filovirus infections is the fact that the nature of epidemics cannot be predicted. Beside the Zaire strain of Ebolavirus other ebolaviruses such as Sudan virus, Bundibugyo virus as well as the more distant relative Marburg virus have caused highly lethal outbreaks. Current experimental vaccines are strictly species-specific and do not provide broad protection against multiple ebolaviruses.

Read More

IBT Receives NIH R01 grant to study the mechanisms of ebolavirus vaccine protection

IBT and University of Maryland receive a collaborative R01 research grant from NIH, Evolution of anti-filovirus B cell responses and mechanisms of protection.

Read More

IBT Receives an SBIR from NIAID for development of a post-exposure vaccine for Streptococcus pneumoniae

IBT receives a SBIR grant from NIH, entitled Serotype independent therapeutic vaccine for Streptococcus pneumoniae.  Antibiotic-resistant bacterial pathogens represent a major challenge within the community, healthcare settings, as well as the military. The growing incidence of bacterial pathogens signals the emergence of the so called “post-antibiotic era”. Vaccines exist only for Antibiotic-resistant bacterial pathogens. Innovative concepts are needed to face these serious challenges of the 21st century.

Read More

Integral Molecular and Integrated BioTherapeutics Initiate Collaboration for Virus Vaccine Discovery

Integral Molecular and Integrated BioTherapeutics have teamed up in the fight against the global health crises posed by Ebola and Zika viruses, signing a collaborative vaccine discovery agreement to help eradicate these threats.

Read More

International Society for Antiviral Research (ISAR) News Vol. 26 No.2

Javad Aman, the Chief Scientific Officer of Integrated BioTherapeutics Inc., is featured in the October 2016 Newsletter of the International Society for Antiviral Research (ISAR). Click to access the article and learn more about Javad’s career path and how he started the company.

Read More

IBT Announces Licensing Agreement with Emergent BioSolutions for Development of Equine Immunoglobulin Therapeutics for Filovirus Infections

Integrated BioTherapeutics (IBT) announced today that it has entered into an exclusive worldwide license agreement with Emergent BioSolutions Inc. (NYSE: EBS) whereby Emergent will gain exclusive rights to use IBT’s proprietary vaccine antigens and know-how in a joint research, development, and manufacturing collaboration focused on an equine-based hyperimmunoglobulin for the treatment of hemorrhagic fever caused by Filoviruses.  Financial terms of the agreement are not disclosed. 

Read More

July 18, 2016
IBT Receives an SBIR from NIAID to engineer an Ebola Antibody to Achieve broad Filovirus Protection

Under this SBTR, IBT will work with Visterra, Inc. (Cambridge, MA) and US Army Medical Research Institute of Infectious Diseases (USAMRIID) to engineer a broadly reactive monoclonal antibody that only neutralizes ebolavirus species to achieve neutralizing activity towards Marburg virus.

Read More

July 17, 2016
IBT Receives an STTR from NIAID for development of Bispecific Antibodies against multiple Ebolaviruses

Under this STTR, IBT will work with Dr. Jon Lai at the Albert Einstein College of Medicine (AECOM) to generate a series of novel bispecific antibodies that target multiple broadly neutralizing epitopes in filovirus glycoprotein. A novel paradigm for fighting filovirus infections. 

Read More

April 26, 2016
Progress Towards a Pan-Ebolavirus Treatment

This study is IBT's first step to demonstrating that ZMappTM can be modified and moved towards a broad reactivity. 

Read More

March 25, 2015
IBT Presents Pan-Ebola and Pan-Filovirus Monoclonal Antibodies

IBT scientists presented the new mAbs at the 7th International Symposium on Filoviruses held in Washington, DC.

Read More

January 13, 2015
Chembio Update on DPP(R) Ebola and DPP(R) Febrile Illness Assays

Chembio Diagnostics, Inc. (Nasdaq:CEMI), a leader in point-of-care (POC) diagnostic tests for infectious diseases, today announced its progress in the development of DPP® Ebola and DPP® Febrile Illness Assays

Read More

October 27, 2014
Integrated BioTherapeutics Partners With Chembio

Chembio Diagnostics, Inc. (Nasdaq:CEMI), a leader in point-of-care (POC) diagnostic tests for infectious diseases.

Read More

July 2, 2014
IBT Secures Another SBIR to Discover Staph Vaccines

NIAID has awarded the company a 2 year, $600,000 grant entitled "In vivo conjugated multivalent toxoid-polysaccharide vaccine for S. aureus."

Read More

May 27, 2014
Data Suggest IBT Investigational Ebola Vaccine Would Protect Wild Apes

The work represents the first time captive chimpanzees have been used for a trial that can benefit their own species rather than humans.

Read More

June 10, 2013
IBT and Stanford Awarded STTR

Integrated BioTherapeutics (IBT) and Stanford University have been jointly awarded a $300,000 Small Business Technology Transfer (STTR) grant.

Read More

February 26, 2013
New Bioterrorism Vaccine Gets First Test In Humans

Integrated BioTherapeutics (IBT) announces the initiation of a Phase 1 clinical trial testing the safety and immunogenicity of its staphylococcal enterotoxin B vaccine "STEBVAX" in healthy adults.

Read More

August 22, 2012
SBIR Award: Integrated BioTherapeutics

The company will receive nearly $600,000 for work to take place over the next two years under principal investigator Dr. M. Javad Aman, President and CSO of IBT.

Read More

July 11, 2012
SBIR Award: Integrated BioTherapeutics

Integrated BioTherapeutics (IBT) has been awarded a Phase I Small Business Innovative Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID), a division of the NIH. 

Read More

June 13, 2012
New Publication from the Researchers at IBT

Efforts to develop effective vaccines against Staphylococcus aureus (S. aureus) have been largely unsuccessful, in part due to the variety of virulence factors produced by this organism.

Read More

Publications

Immunization-Elicited Broadly Protective Antibody Reveals Ebolavirus Fusion Loop as a Site of Vulnerability.  Zhao X, Howell KA, He S, Brannan JM, Wec AZ, Davidson E, Turner HL, Chiang CI, Lei L, Fels JM, Vu H, Shulenin S, Turonis AN, Kuehne AI, Liu G, Ta M, Wang Y, Sundling C, Xiao Y, Spence JS, Doranz BJ, Holtsberg FW, Ward AB, Chandran K, Dye JM, Qiu X, Li Y, Aman MJ.  Cell. 2017 May 18;169(5):891-904.e15. doi: 10.1016/j.cell.2017.04.038.

Read More 

Cooperativity Enables Non-neutralizing Antibodies to Neutralize Ebolavirus.  Howell KA, Brannan JM, Bryan C, McNeal A, Davidson E, Turner HL, Vu H, Shulenin S, He S, Kuehne A, Herbert AS, Qiu X, Doranz BJ, Holtsberg FW, Ward AB, Dye JM, Aman MJ.  Cell Rep. 2017 Apr 11;19(2):413-424. doi: 10.1016/j.celrep.2017.03.049.

Read More 

Protective efficacy of a novel alpha hemolysin subunit vaccine (AT62) against Staphylococcus aureus skin and soft tissue infections.  Adhikari RP, Thompson CD, Aman MJ, Lee JC.  Vaccine. 2016 Dec 7;34(50):6402-6407. doi:10.1016/j.vaccine.2016.09.061. Epub 2016 Nov 12.
 

Read More 

Safety and Immunogenicity of a Parenterally Administered, Structure-Based Rationally Modified Recombinant Staphylococcal Enterotoxin B Protein Vaccine, STEBVax. Chen WH, Pasetti MF, Adhikari RP, Baughman H, Douglas R, El-Khorazaty J, Greenberg N, Holtsberg FW, Liao GC, Reymann MK, Wang X, Warfield KL, Aman MJ. Clin Vaccine Immunol. 2016 Dec 5;23(12):918-925. Print 2016 Dec.
 

Read More 

A "Trojan Horse" Bispecific Antibody Strategy for Broad Protection against Ebolaviruses. Wec, A.Z. Nyakatura, E.K. Herbert, A.S. Howell, K.A. Holtsberg, F.W. Bakken, R.R. Mittler, E. Christin, J.R. Shulenin, S. Jangra, R.K. Bharrhan, S. Kuehne, A.I. Bornholdt, Z.A. Flyak, A.I. Saphire, E. Crowe Jr., J.E. Aman, M.J. Dye, J.M. Lai, J.R. Chandran, K. (2016) Science 8(2016). doi: 10.1126/science.aag3267

Read More 

Feverish Quest for Ebola Immunotherapy: Straight or Cocktail?  Aman, M.J. Saphire, EO. (2016) Trends Microbiol 10(1016). pii: SD966-842X(16)30049-X

Read More 

Zika Virus: A New Animal Model for an Arbovirus.  Aman, M.J. Kashanchi, F. (2016) PLoS Negl Trop Dis 10(5): e0004702. doi:10.1371/journal.pntd.0004702

Read More 

Virus-Like Particle Vaccination Protects Nonhuman Primates from Lethal Aerosol Exposure with Marburgvirus (VLP Vaccination Protects Macaques against Aerosol Challenges).  Dye JM, Warfield KL, Wells JB, Unfer RC, Shulenin S, Vu H, Nichols DK, Aman MJ, Bavari S. Viruses. 2016 Apr 8;8(4). pii: E94. doi: 10.3390/v8040094

Read More 

Antibody Treatment of Ebola and Sudan Virus Infection via a Uniquely Exposed Epitope within the Glycoprotein Receptor-Binding Site.  Howell KA, Qiu X, Brannan JM, Bryan C, Davidson E, Holtsberg FW, Wec AZ, Shulenin S, Biggins JE, Douglas R, Enterlein SG, Turner HL, Pallesen J, Murin CD, He S, Kroeker K, Vu H, Herbert AS, Fusco ML, Nyakatura EK, Lai JR, Keck ZY, Foung SKH, Saphire EO, Zeitlin L, Ward AB, Chandran K, Doranz BJ, Kobinger GP, Dye JM, Aman MJ. (2016) Cell Reports 15, 1–13.

Read More 

Monoclonal antibody therapy for Junin virus infection.  Zeitlin L, Geisbert JB, Deer DJ, Fenton KA, Bohorov O, Bohorova N, Goodman C, Kim D, Hiatt A, Pauly MH, Velasco J, Whaley KJ, Altmann F, Gruber C, Steinkellner H, Honko AN, Kuehne AI, Aman MJ, Sahandi S, Enterlein S, Zhan X, Enria D, Geisbert TW. Proc Natl Acad Sci U S A. 2016 Apr 19;113(16):4458-63.

Read More 

Aman MJ, Chasing Ebola through the Endosomal Labyrinth:, MBio, 2016, 7(2):e00346-16

Read More 

Holtsberg et al., Pan-ebolavirus and Pan-filovirus Mouse Monoclonal Antibodies: Protection against Ebola and Sudan Viruses, J Virol, 2014

Read More 

Keck et al., Macaque Monoclonal Antibodies Targeting Novel Conserved Epitopes within Filovirus Glycoprotein, J Virol, 2014

Read More

Adhikari et al., Antibodies to S. aureus LukS-PV Attenuated Subunit Vaccine Neutralize a Broad Spectrum of Canonical and Non-Canonical Bicomponent Leukotoxin Pairs, PLoS One, 2015

Read More

Fusco et al., Protective mAbs and Cross-Reactive mAbs Raised by Immunization with Engineered Marburg Virus GPs, PLoS Pathog, 2015

Read More

Warfield et al., Homologous and heterologous protection of nonhuman primates by Ebola and Sudan virus-like particles, PLoS One, 2015

Read More

Sully et al., A tripartite cocktail of chimeric monoclonal antibodies passively protects mice against ricin, staphylococcal enterotoxin B and Clostridium perfringens epsilon toxin, Toxicon, 2014

Read More

Warfield et al., Vaccinating captive chimpanzees to save wild chimpanzees, Proc Natl Acad Sci USA, 2014

Read More

Aman and Adhikari, Staphylococcal bicomponent pore-forming toxins: targets for prophylaxis and immunotherapy, Toxins, 2014

Read More

Karauzum et al., Structurally designed attenuated subunit vaccines for S. aureus LukS-PV and LukF-PV confer protection in a mouse bacteremia model, PLoS One, 2013

Read More

Adhikari et al., Lower antibody levels to Staphylococcus aureus exotoxins are associated with sepsis in hospitalized adults with invasive S. aureus infections, J Infect Dis, 2012

Read More

Adhikari et al., Novel structurally designed vaccine for S. aureus α-hemolysin: protection against bacteremia and pneumonia, PLoS One, 2012.

Read More

Contact us for more information    Contact IBT